Prioritization schema for immunotherapy clinical trials in glioblastoma

OncoImmunology

Volumn 5, Issue 6, 2016, Pages

  Hodges, Tiffany R ^a   Ferguson, Sherise D ^a   Caruso, Hillary G ^a   Kohanbash, Gary ^b   Zhou, Shouhao ^a   Cloughesy, Timothy F ^c   Berger, Mitchel S ^b   Poste, George H ^d   Khasraw, Mustafa ^e   Ba, Sujuan ^f,m   Jiang, Tao ^g   Mikkelson, Tom ^h   Yung, W K Alfred ^a   de Groot, John F ^a   Fine, Howard ⁱ   Cantley, Lewis C ^j   Mellinghoff, Ingo K ^k   Mitchell, Duane A ^l   Okada, Hideho ^b   Heimberger, Amy B ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d ARIZONA STATE UNIVERSITY   (United States)

^e UNIVERSITY OF SYDNEY   (Australia)

^f Center for Metastasis Research   (United States)

^g CAPITAL MEDICAL UNIVERSITY   (China)

^h HENRY FORD HEALTH SYSTEM   (United States)

ⁱ WEILL CORNELL MEDICAL COLLEGE   (United States)

^j HARVARD MEDICAL SCHOOL   (United States)

^k MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^l UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^m Asian Fund for Cancer Research   (China)

more..

Author keywords

Clinical trial; glioblastoma; immunotherapy; prioritization; score card

Indexed keywords

ANTINEOPLASTIC AGENT; ARGININE; CHIMERIC ANTIGEN RECEPTOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EPIDERMAL GROWTH FACTOR VARIANT III MONOCLONAL ANTIBODY CD3; FLT3 LIGAND; IDH1 PEPTIDE VACCINE; INTERLEUKIN 12; IPILIMUMAB; JNJ 40346527; NIVOLUMAB; PEMBROLIZUMAB; PEPTIDE APTAMER; PEPTIDE VACCINE; PLX 3397; RINDOPEPIMUT; SMALL MOLECULE INHIBITOR; TRABEDERSEN; UNCLASSIFIED DRUG; VIRUS VECTOR;

ADOPTIVE IMMUNOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL DIFFERENTIATION; DENDRITIC CELL; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GLIOBLASTOMA; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOMODULATION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; REVIEW; SCORING SYSTEM; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT;

EID: 84969610644     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2016.1145332     Document Type: Review

References (228)

1. R.Stupp, W.P.Mason, M.J.van den Bent, M.Weller, B.Fisher, M.J.Taphoorn, K.Belanger, A.A.Brandes, C.Marosi, U.Bogdahn et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352:987-96; PMID:15758009; 10.1056/NEJMoa043330
2. GBM AGILE (An Adaptive, Global, Innovative Learning Environment) to Implement Unprecedented International Clinical Trial. National Biomarker Development Alliance 2015; http://nbdabiomarkers.org/gbm-agile
3. D.Moher, A.Liberati, J.Tetzlaff, D.G.Altman, P.Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009; 151:264-9, W64; PMID:19622511; 10.7326/0003-4819-151-4-200908180-00135
4. A.B.Heimberger, L.E.Crotty, G.E.Archer, K.R.Hess, C.J.Wikstrand, A.H.Friedman, H.S.Friedman, D.D.Bigner, J.H.Sampson. Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin Cancer Res 2003; 9:4247-54; PMID:14519652
5. J.H.Sampson, L.E.Crotty, S.Lee, G.E.Archer, D.M.Ashley, C.J.Wikstrand, L.P.Hale, C.Small, G.Dranoff, A.H.Friedman et al. Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors. Proc Natl Acad Sci U S A 2000; 97:7503-8; PMID:10852962; 10.1073/pnas.130166597
6. A.Murat, E.Migliavacca, T.Gorlia, W.L.Lambiv, T.Shay, M.F.Hamou, N.de Tribolet, L.Regli, W.Wick, M.C.Kouwenhoven et al. Stem cell-related “self-renewal” signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol 2008; 26:3015-24; PMID:18565887; 10.1200/JCO.2007.15.7164
7. J.Wei, J.Barr, L.Y.Kong, Y.Wang, A.Wu, A.K.Sharma, J.Gumin, V.Henry, H.Colman, W.Priebe et al. Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway. Mol Cancer Ther 2010; 9:67-78; PMID:20053772; 10.1158/1535-7163.MCT-09-0734
8. D.A.Wainwright, A.L.Chang, M.Dey, I.V.Balyasnikova, C.Kim, A.L.Tobias, Y.Cheng, J.Kim, J.Qiao, L.Zhang et al. Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4 and PD-L1 in mice with brain tumors. Clin Cancer Res 2014; 20:5290-301; PMID:24691018; 10.1158/1078-0432.CCR-14-0514
9. A.S.Berghoff, B.Kiesel, G.Widhalm, O.Rajky, G.Ricken, A.Wohrer, K.Dieckmann, M.Filipits, A.Brandstetter, M.Weller et al. Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. Neuro Oncol 2015; 17:1064-75; PMID:25355681; 10.1093/neuonc/nou307
10. E.K.Nduom, J.Wei, N.K.Yaghi, N.Huang, L.Y.Kong, K.Gabrusiewicz, X.Ling, S.Zhou, C.Ivan, J.Q.Chen et al. PD-L1 expression and prognostic impact in glioblastoma. Neuro Oncol In Press.
11. H.R.Ali, S.E.Glont, F.M.Blows, E.Provenzano, S.J.Dawson, B.Liu, L.Hiller, J.Dunn, C.J.Poole, S.Bowden et al. PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes. Ann Oncol 2015; 26:1488-93; PMID:25897014; 10.1093/annonc/mdv518.22
12. S.P.D'Angelo, A.N.Shoushtari, N.P.Agaram, D.Kuk, L.X.Qin, R.D.Carvajal, M.A.Dickson, M.Gounder, M.L.Keohan, G.K.Schwartz et al. Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment. Hum Pathol 2015; 46:357-65; PMID:25540867; 10.1016/j.humpath.2014.11.001
13. A.Testori, J.Richards, E.Whitman, G.B.Mann, J.Lutzky, L.Camacho, G.Parmiani, G.Tosti, J.M.Kirkwood, A.Hoos et al. Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group. J Clin Oncol 2008; 26:955-62; PMID:18281670; 10.1200/JCO.2007.11.9941
14. C.Wood, P.Srivastava, R.Bukowski, L.Lacombe, A.I.Gorelov, S.Gorelov, P.Mulders, H.Zielinski, A.Hoos, F.Teofilovici et al. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet 2008; 372:145-54; PMID:18602688; 10.1016/S0140-6736(08)60697-2
15. C.Cobbs, L.Harkins, M.Samanta, G.Gillespie, S.Bharara, P.King, L.Nabors, C.Cobbs, W.Britt. Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res 2002; 62:3347-50; PMID:12067971
16. D.A.Mitchell, W.Xie, R.Schmittling, C.Learn, A.Friedman, R.E.McLendon, J.H.Sampson. Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. Neuro Oncol 2008; 10:10-8; PMID:17951512; 10.1215/15228517-2007-035
17. P.Ranganathan, P.A.Clark, J.S.Kuo, M.S.Salamat, R.F.Kalejta. Significant association of multiple human cytomegalovirus genomic Loci with glioblastoma multiforme samples. J Virol 2012; 86:854-64; PMID:22090104; 10.1128/JVI.06097-11
18. S.E.Lawler. Cytomegalovirus and glioblastoma; controversies and opportunities. J Neurooncol 2015; 123:465-71; PMID:25682092; 10.1007/s11060-015-1734-0
19. W.Wick, M.Platten. CMV infection and glioma, a highly controversial concept struggling in the clinical arena. Neuro Oncol 2014; 16:332-3; PMID:24523454; 10.1093/neuonc/nou002
20. C.S.Cobbs, L.Soroceanu, S.Denham, W.Zhang, M.H.Kraus. Modulation of oncogenic phenotype in human glioma cells by cytomegalovirus IE1-mediated mitogenicity. Cancer Res 2008; 68:724-30; PMID:18245472; 10.1158/0008-5472.CAN-07-2291
21. G.Stragliotto, A.Rahbar, N.W.Solberg, A.Lilja, C.Taher, A.Orrego, B.Bjurman, C.Tammik, P.Skarman, I.Peredo et al. Effects of valganciclovir as an add-on therapy in patients with cytomegalovirus-positive glioblastoma: a randomized, double-blind, hypothesis-generating study. Int J Cancer 2013; 133:1204-13; PMID:23404447; 10.1002/ijc.28111
22. D.A.Mitchell, K.A.Batich, M.D.Gunn, M.N.Huang, L.Sanchez-Perez, S.K.Nair, K.L.Congdon, E.A.Reap, G.E.Archer, A.Desjardins et al. Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature 2015; 519:366-9; PMID:25762141; 10.1038/nature14320
23. D.K.Moscatello, M.Holgado-Madruga, A.K.Godwin, G.Ramirez, G.Gunn, P.W.Zoltick, J.A.Biegel, R.L.Hayes, A.J.Wong. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Research 1995; 55:5536-9; PMID:7585629
24. N.Shinojima, K.Tada, S.Shiraishi, T.Kamiryo, M.Kochi, H.Nakamura, K.Makino, H.Saya, H.Hirano, J.Kuratsu et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 2003; 63:6962-70; PMID:14583498
25. C.J.Wikstrand, R.E.McLendon, A.H.Friedman, D.D.Bigner. Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. Cancer Res 1997; 57:4130-40; PMID:9307304
26. A.B.Heimberger, R.Hlatky, D.Suki, D.Yang, J.Weinberg, M.Gilbert, R.Sawaya, K.Aldape. Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res 2005; 11:1462-6; PMID:15746047; 10.1158/1078-0432.CCR-04-1737
27. J.H.Sampson, A.B.Heimberger, G.E.Archer, K.D.Aldape, A.H.Friedman, H.S.Friedman, M.R.Gilbert, J.E.Herndon, 2nd, R.E.McLendon, D.A.Mitchell et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol 2010; 28:4722-9; PMID:20921459; 10.1200/JCO.2010.28.6963
28. D.A.Reardon, J.M.Schuster, D.D.Tran, K.L.Fink, L.B.Nabors, G.Li, D.A.Bota, R.V.Lukas, A.Desjardins, L.S.Ashby et al. 107 ReACT: Overall Survival From a Randomized Phase II Study of Rindopepimut (CDX-110) Plus Bevacizumab in Relapsed Glioblastoma. Neurosurgery 2015; 62 Suppl 1:198-9; 10.1227/01.neu.0000467069.86811.3f
29. J.Schuster, R.K.Lai, L.D.Recht, D.A.Reardon, N.A.Paleologos, M.D.Groves, M.M.Mrugala, R.Jensen, J.M.Baehring, A.Sloan et al. A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study. Neuro Oncol 2015; 17:854-61; PMID:25586468; 10.1093/neuonc/nou348
30. M.K.Hunn, E.Bauer, C.E.Wood, O.Gasser, M.Dzhelali, L.R.Ancelet, B.Mester, K.J.Sharples, M.P.Findlay, D.A.Hamilton et al. Dendritic cell vaccination combined with temozolomide retreatment: results of a phase I trial in patients with recurrent glioblastoma multiforme. J Neurooncol 2015; 121:319-29; PMID:25366363; 10.1007/s11060-014-1635-7
31. H.Okada, P.Kalinski, R.Ueda, A.Hoji, G.Kohanbash, T.E.Donegan, A.H.Mintz, J.A.Engh, D.L.Bartlett, C.K.Brown et al. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol 2011; 29:330-6; PMID:21149657; 10.1200/JCO.2010.30.7744
32. H.Ardon, S.Van Gool, I.S.Lopes, W.Maes, R.Sciot, G.Wilms, P.Demaerel, P.Bijttebier, L.Claes, J.Goffin et al. Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study. J Neurooncol 2010; 99:261-72; PMID:20146084; 10.1007/s11060-010-0131-y
33. H.Ardon, S.W.Van Gool, T.Verschuere, W.Maes, S.Fieuws, R.Sciot, G.Wilms, P.Demaerel, J.Goffin, F.Van Calenbergh et al. Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial. Cancer Immunol Immun 2012 Nov; 61(11):2033-44; PMID:22527250; 10.1007/s00262-012-1261-1.
34. R.G.Everson, R.M.Jin, X.Wang, M.Safaee, R.Scharnweber, D.N.Lisiero, H.Soto, L.M.Liau, R.M.Prins. Cytokine responsiveness of CD8(+) T cells is a reproducible biomarker for the clinical efficacy of dendritic cell vaccination in glioblastoma patients. J Immunother Cancer 2014; 2:10; PMID:24883189; 10.1186/2051-1426-2-10
35. L.M.Liau, R.M.Prins, S.M.Kiertscher, S.K.Odesa, T.J.Kremen, A.J.Giovannone, J.W.Lin, D.J.Chute, P.S.Mischel, T.F.Cloughesy et al. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res 2005; 11:5515-25; PMID:16061868; 10.1158/1078-0432.CCR-05-0464
36. J.S.Yu, C.J.Wheeler, P.M.Zeltzer, H.Ying, D.N.Finger, P.K.Lee, W.H.Yong, F.Incardona, R.C.Thompson, M.S.Riedinger et al. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Research 2001; 61:842-7; PMID:11221866
37. S.K.Nair, G.De Leon, D.Boczkowski, R.Schmittling, W.Xie, J.Staats, R.Liu, L.A.Johnson, K.Weinhold, G.E.Archer et al. Recognition and killing of autologous, primary glioblastoma tumor cells by human cytomegalovirus pp65-specific cytotoxic T cells. Clin Cancer Res 2014; 20:2684-94; PMID:24658154; 10.1158/1078-0432.CCR-13-3268
38. R.M.Prins, T.F.Cloughesy, L.M.Liau. Cytomegalovirus immunity after vaccination with autologous glioblastoma lysate. N Engl J Med 2008; 359:539-41; PMID:18669440; 10.1056/NEJMc0804818
39. P.Yu, Y.Lee, W.Liu, R.K.Chin, J.Wang, Y.Wang, A.Schietinger, M.Philip, H.Schreiber, Y.X.Fu. Priming of naive T cells inside tumors leads to eradication of established tumors.[see comment]. Nat Immunol 2004; 5:141-9; PMID:14704792; 10.1038/ni1029
40. J.Yu, G.Liu, H.Ying, W.Yong, K.Black, C.J.Wheeler. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res 2004; 64:4973-9; PMID:15256471; 10.1158/0008-5472.CAN-03-3505
41. C.Kjellman, S.P.Olofsson, O.Hansson, T.Von Schantz, M.Lindvall, I.Nilsson, L.G.Salford, H.O.Sjogren, B.Widegren. Expression of TGF-beta isoforms, TGF-beta receptors, and SMAD molecules at different stages of human glioma. Int J Cancer 2000; 89:251-8; PMID:10861501; 10.1002/1097-0215(20000520)89:3%3c251::AID-IJC7%3e3.0.CO;2-5
42. M.Maxwell, T.Galanopoulos, J.Neville-Golden, H.N.Antoniades. Effect of the expression of transforming growth factor-beta 2 in primary human glioblastomas on immunosuppression and loss of immune surveillance. JNeurosurg 1992; 76:799-804; 10.3171/jns.1992.76.5.0799
43. P.Jachimczak, U.Bogdahn, J.Schneider, C.Behl, J.Meixensberger, R.Apfel,, R.Dorries, K.H.Schlingensiepen, W.Brysch. The effect of transforming growth factor-beta 2-specific phosphorothioate-anti-sense oligodeoxynucleotides in reversing cellular immunosuppression in malignant glioma. JNeurosurg 1993; 78:944-51; 10.3171/jns.1993.78.6.0944
44. P.Jachimczak, B.Hessdorfer, K.Fabel-Schulte, C.Wismeth, W.Brysch, K.H.Schlingensiepen, A.Bauer, A.Blesch, U.Bogdahn. Transforming growth factor-beta-mediated autocrine growth regulation of gliomas as detected with phosphorothioate antisense oligonucleotides. Int J Cancer 1996; 65:332-7; PMID:8575854; 10.1002/(SICI)1097-0215(19960126)65:3%3c332::AID-IJC10%3e3.0.CO;2-C
45. P.Hau, P.Jachimczak, R.Schlingensiepen, F.Schulmeyer, T.Jauch, A.Steinbrecher, A.Brawanski, M.Proescholdt, J.Schlaier, J.Buchroithner et al. Inhibition of TGF-beta2 with AP 12009 in recurrent malignant gliomas: from preclinical to phase I/II studies. Oligonucleotides 2007; 17:201-12; PMID:17638524; 10.1089/oli.2006.0053
46. U.Bogdahn, P.Hau, G.Stockhammer, N.K.Venkataramana, A.K.Mahapatra, A.Suri, A.Balasubramaniam, S.Nair, V.Oliushine, V.Parfenov et al. Targeted therapy for high-grade glioma with the TGF-beta2 inhibitor trabedersen: results of a randomized and controlled phase IIb study. Neuro Oncol 2011; 13:132-42; PMID:20980335; 10.1093/neuonc/noq142
47. F.S.Hodi, S.J.O'Day, D.F.McDermott, R.W.Weber, J.A.Sosman, J.B.Haanen, R.Gonzalez, C.Robert, D.Schadendorf, J.C.Hassel et al. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. N Engl J Med 2010; 363:711-23; PMID:20525992; 10.1056/NEJMoa1003466
48. O.Hamid, C.Robert, A.Daud, F.S.Hodi, W.J.Hwu, R.Kefford, J.D.Wolchok, P.Hersey, R.W.Joseph, J.S.Weber et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013; 369:134-44; PMID:23724846; 10.1056/NEJMoa1305133
49. C.Robert, A.Ribas, J.D.Wolchok, F.S.Hodi, O.Hamid, R.Kefford, J.S.Weber, A.M.Joshua, W.J.Hwu, T.C.Gangadhar et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014; 384:1109-17; PMID:25034862; 10.1016/S0140-6736(14)60958-2
50. S.L.Topalian, M.Sznol, D.F.McDermott, H.M.Kluger, R.D.Carvajal, W.H.Sharfman, J.R.Brahmer, D.P.Lawrence, M.B.Atkins, J.D.Powderly et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014; 32:1020-30; PMID:24590637; 10.1200/JCO.2013.53.0105
51. J.Larkin, V.Chiarion-Sileni, R.Gonzalez, J.J.Grob, C.L.Cowey, C.D.Lao, D.Schadendorf, R.Dummer, M.Smylie, P.Rutkowski et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med 2015; 373:23-34; PMID:26027431; 10.1056/NEJMoa1504030
52. A.B.Heimberger, M.Abou-Ghazal, C.Reina-Ortiz, D.S.Yang, W.Sun, W.Qiao, N.Hiraoka, G.N.Fuller. Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas. Clin Cancer Res 2008; 14:5166-72; PMID:18698034; 10.1158/1078-0432.CCR-08-0320
53. D.A.Mitchell, X.Cui, R.J.Schmittling, L.Sanchez-Perez, D.J.Snyder, K.L.Congdon, G.E.Archer, A.Desjardins, A.H.Friedman, H.S.Friedman et al. Monoclonal antibody blockade of IL-2 receptor alpha during lymphopenia selectively depletes regulatory T cells in mice and humans. Blood 2011; 118:3003-12; PMID:21768296; 10.1182/blood-2011-02-334565
54. J.H.Sampson, R.J.Schmittling, G.E.Archer, K.L.Congdon, S.K.Nair, E.A.Reap, A.Desjardins, A.H.Friedman, H.S.Friedman, J.E.Herndon, 2nd et al. A pilot study of IL-2Ralpha blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma. PLoS One 2012; 7:e31046; PMID:22383993; 10.1371/journal.pone.0031046
55. R.Gold, G.Giovannoni, K.Selmaj, E.Havrdova, X.Montalban, E.W.Radue, D.Stefoski, R.Robinson, K.Riester, J.Rana et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet 2013; 381:2167-75; PMID:23562009; 10.1016/S0140-6736(12)62190-4
56. S.F.Hussain, D.Yang, D.Suki, K.Aldape, E.Grimm, A.B.Heimberger. The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neuro Oncol 2006; 8:261-79; PMID:16775224; 10.1215/15228517-2006-008
57. Y.Komohara, K.Ohnishi, J.Kuratsu, M.Takeya. Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas. J Pathol 2008; 216:15-24; PMID:18553315; 10.1002/path.2370
58. S.M.Pyonteck, L.Akkari, A.J.Schuhmacher, R.L.Bowman, L.Sevenich, D.F.Quail, O.C.Olson, M.L.Quick, J.T.Huse, V.Teijeiro et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med 2013; 19:1264-72; PMID:24056773; 10.1038/nm.3337
59. C.H.Ries, S.Hoves, M.A.Cannarile, D.Ruttinger. CSF-1/CSF-1R targeting agents in clinical development for cancer therapy. Curr Opin Pharmacol 2015; 23:45-51; PMID:26051995; 10.1016/j.coph.2015.05.008
60. B.von Tresckow, F.Morschhauser, V.Ribrag, M.S.Topp, C.Chien, S.Seetharam, R.Aquino, S.Kotoulek, C.J.de Boer, A.Engert. An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed or Refractory Hodgkin Lymphoma. Clin Cancer Res 2015; 21:1843-50; PMID:25628399; 10.1158/1078-0432.CCR-14-1845
61. T.Crough, L.Beagley, C.Smith, L.Jones, D.G.Walker, R.Khanna. Ex vivo functional analysis, expansion and adoptive transfer of cytomegalovirus-specific T-cells in patients with glioblastoma multiforme. Immunol Cell Biol 2012; 90:872-80; PMID:22508289; 10.1038/icb.2012.19
62. R.O.Dillman, C.M.Duma, R.A.Ellis, A.N.Cornforth, P.M.Schiltz, S.L.Sharp, M.C.DePriest. Intralesional lymphokine-activated killer cells as adjuvant therapy for primary glioblastoma. J Immunother 2009; 32:914-9; PMID:19816190; 10.1097/CJI.0b013e3181b2910f
63. R.O.Dillman, C.M.Duma, P.M.Schiltz, C.DePriest, R.A.Ellis, K.Okamoto, L.D.Beutel, C.De Leon, S.Chico. Intracavitary placement of autologous lymphokine-activated killer (LAK) cells after resection of recurrent glioblastoma. J Immunother 2004; 27:398-404; PMID:15314549; 10.1097/00002371-200409000-00009
64. E.Ishikawa, K.Tsuboi, K.Saijo, H.Harada, S.Takano, T.Nose, T.Ohno. Autologous natural killer cell therapy for human recurrent malignant glioma. Anticancer Res 2004; 24:1861-71; PMID:15274367
65. A.Schuessler, C.Smith, L.Beagley, G.M.Boyle, S.Rehan, K.Matthews, L.Jones, T.Crough, V.Dasari, K.Klein et al. Autologous T-cell therapy for cytomegalovirus as a consolidative treatment for recurrent glioblastoma. Cancer Res 2014; 74:3466-76; PMID:24795429; 10.1158/0008-5472.CAN-14-0296
66. B.D.Choi, C.M.Suryadevara, P.C.Gedeon, J.E.Herndon, 2nd, L.Sanchez-Perez, D.D.Bigner, J.H.Sampson. Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human glioma. J Clin Neurosci 2014; 21:189-90; PMID:24054399; 10.1016/j.jocn.2013.03.012
67. H.Miao, B.D.Choi, C.M.Suryadevara, L.Sanchez-Perez, S.Yang, G.De Leon, E.J.Sayour, R.McLendon, J.E.Herndon, 2nd, P.Healy et al. EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma. PLoS One 2014; 9:e94281; PMID:24722266; 10.1371/journal.pone.0094281
68. L.A.Johnson, J.Scholler, T.Ohkuri, A.Kosaka, P.R.Patel, S.E.McGettigan, A.K.Nace, T.Dentchev, P.Thekkat, A.Loew et al. Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma. Sci Transl Med 2015; 7:275ra22; PMID:25696001; 10.1126/scitranslmed.aaa4963
69. M.Ohno, T.Ohkuri, A.Kosaka, K.Tanahashi, C.H.June, A.Natsume, H.Okada. Expression of miR-17-92 enhances anti-tumor activity of T-cells transduced with the anti-EGFRvIII chimeric antigen receptor in mice bearing human GBM xenografts. J Immunother Cancer 2013; 1:21; PMID:24829757; 10.1186/2051-1426-1-21
70. C.E.Brown, B.Badie, M.E.Barish, L.Weng, J.R.Ostberg, W.C.Chang, A.Naranjo, R.Starr, J.Wagner, C.Wright et al. Bioactivity and Safety of IL13Ralpha2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma. Clin Cancer Res 2015; 21(18):4062-72; PMID:26059190; 10.1158/1078-0432.CCR-15-0428.
71. H.G.Caruso, L.V.Hurton, A.Najjar, D.Rushworth, S.Ang, S.Olivares, T.Mi, K.Switzer, H.Singh, H.Huls, et al. Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity. Cancer Res 2015; 75(17):3505–18; PMID:26330164; 10.1158/0008-5472.CAN-15-0139.
72. M.Abou-Ghazal, D.S.Yang, W.Qiao, C.Reina-Ortiz, J.Wei, L.Y.Kong, G.N.Fuller, N.Hiraoka, W.Priebe, R.Sawaya et al. The incidence, correlation with tumor-infiltrating inflammation, and prognosis of phosphorylated STAT3 expression in human gliomas. Clin Cancer Res 2008; 14:8228-35; PMID:19088040; 10.1158/1078-0432.CCR-08-1329
73. S.Huang. Regulation of metastases by signal transducer and activator of transcription 3 signaling pathway: clinical implications. Clin Cancer Res 2007; 13:1362-6; PMID:17332277; 10.1158/1078-0432.CCR-06-2313
74. H.Yu, R.Jove. The STATs of cancer–new molecular targets come of age. Nat Rev Cancer 2004; 4:97-105; PMID:14964307; 10.1038/nrc1275
75. H.Yu, M.Kortylewski, D.Pardoll. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007; 7:41-51; PMID:17186030; 10.1038/nri1995
76. L.Y.Kong, J.Wei, A.K.Sharma, J.Barr, M.K.Abou-Ghazal, I.Fokt, J.Weinberg, G.Rao, E.Grimm, W.Priebe et al. A novel phosphorylated STAT3 inhibitor enhances T cell cytotoxicity against melanoma through inhibition of regulatory T cells. Cancer Immunol Immunother 2009; 58:1023-32; PMID:19002459; 10.1007/s00262-008-0618-y
77. Y.Nefedova, M.Huang, S.Kusmartsev, R.Bhattacharya, P.Cheng, R.Salup, R.Jove, D.Gabrilovich. Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer. J Immunol 2004; 172:464-74; PMID:14688356; 10.4049/jimmunol.172.1.464
78. Y.Nefedova, S.Nagaraj, A.Rosenbauer, C.Muro-Cacho, S.M.Sebti, D.I.Gabrilovich. Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathway. Cancer Res 2005; 65:9525-35; PMID:16230418; 10.1158/0008-5472.CAN-05-0529
79. M.M.Sherry, A.Reeves, J.K.Wu, B.H.Cochran. STAT3 is required for proliferation and maintenance of multipotency in glioblastoma stem cells. Stem Cells 2009; 27:2383-92; PMID:19658181; 10.1002/stem.185
80. J.Wei, J.Barr, L.Y.Kong, Y.Wang, A.Wu, A.K.Sharma, J.Gumin, V.Henry, H.Colman, R.Sawaya et al. Glioma-associated cancer-initiating cells induce immunosuppression. Clin Cancer Res 2010; 16:461-73; PMID:20068105; 10.1158/1078-0432.CCR-09-1983
81. T.Ashizawa, H.Miyata, A.Iizuka, M.Komiyama, C.Oshita, A.Kume, M.Nogami, M.Yagoto, I.Ito, T.Oishi et al. Effect of the STAT3 inhibitor STX-0119 on the proliferation of cancer stem-like cells derived from recurrent glioblastoma. Int J Oncol 2013; 43:219-27; PMID:23612755; 10.3892/ijo.2013.1916
82. E.R.Plimack, P.M.Lorusso, P.McCoon, W.Tang, A.D.Krebs, G.Curt, S.G.Eckhardt. AZD1480: a phase I study of a novel JAK2 inhibitor in solid tumors. Oncologist 2013; 18:819-20; PMID:23847256; 10.1634/theoncologist.2013-0198
83. R.Zielinski, A.Rusin, T.Madden, C.Conrad, M.Johansen, I.Fokt, S.Skora, A.Jayakumar, A.Heimberger, W.Priebe. Abstract 4540:Development of orally bioavailable formulatin of WP1066 and its evaluation in vivo. AACR 106th Annual Meeting. Philadelphia, PA: Cancer Res, 2015.
84. B.D.Choi, P.C.Gedeon, L.Sanchez-Perez, D.D.Bigner, J.H.Sampson. Regulatory T cells are redirected to kill glioblastoma by an EGFRvIII-targeted bispecific antibody. Oncoimmunology 2013; 2:e26757; PMID:24475376; 10.4161/onci.26757
85. H.Yan, D.W.Parsons, G.Jin, R.McLendon, B.A.Rasheed, W.Yuan, I.Kos, I.Batinic-Haberle, S.Jones, G.J.Riggins et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009; 360:765-73; PMID:19228619; 10.1056/NEJMoa0808710
86. D.W.Parsons, S.Jones, X.Zhang, J.C.Lin, R.J.Leary, P.Angenendt, P.Mankoo, H.Carter, I.M.Siu, G.L.Gallia et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008; 321:1807-12; PMID:18772396; 10.1126/science.1164382
87. S.Pellegatta, L.Valletta, C.Corbetta, M.Patane, I.Zucca, F.Riccardi Sirtori, M.G.Bruzzone, G.Fogliatto, A.Isacchi, B.Pollo et al. Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma. Acta neuropathologica communications 2015; 3:4; PMID:25849072; 10.1186/s40478-014-0180-0
88. T.Schumacher, L.Bunse, S.Pusch, F.Sahm, B.Wiestler, J.Quandt, O.Menn, M.Osswald, I.Oezen, M.Ott et al. A vaccine targeting mutant IDH1 induces antitumour immunity. Nature 2014; 512:324-7; PMID:25043048; 10.1038/nature13387
89. E.K.Hellums, J.M.Markert, J.N.Parker, B.He, B.Perbal, B.Roizman, R.J.Whitley, C.P.Langford, S.Bharara, G.Y.Gillespie. Increased efficacy of an interleukin-12-secreting herpes simplex virus in a syngeneic intracranial murine glioma model. Neuro Oncol 2005; 7:213-24; PMID:16053696; 10.1215/S1152851705000074
90. J.M.Markert, J.J.Cody, J.N.Parker, J.M.Coleman, K.H.Price, E.R.Kern, D.C.Quenelle, A.D.Lakeman, T.R.Schoeb, C.A.Palmer et al. Preclinical evaluation of a genetically engineered herpes simplex virus expressing interleukin-12. J Virol 2012; 86:5304-13; PMID:22379082; 10.1128/JVI.06998-11
91. J.N.Parker, G.Y.Gillespie, C.E.Love, S.Randall, R.J.Whitley, J.M.Markert. Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors. Proc Natl Acad Sci U S A 2000; 97:2208-13; PMID:10681459; 10.1073/pnas.040557897
92. H.Wakimoto, S.Kesari, C.J.Farrell, W.T.Curry, Jr., C.Zaupa, M.Aghi, T.Kuroda, A.Stemmer-Rachamimov, K.Shah, T.C.Liu et al. Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. Cancer Res 2009; 69:3472-81; PMID:19351838; 10.1158/0008-5472.CAN-08-3886
93. J.C.Roth, K.A.Cassady, J.J.Cody, J.N.Parker, K.H.Price, J.M.Coleman, J.O.Peggins, P.E.Noker, N.W.Powers, S.D.Grimes et al. Evaluation of the safety and biodistribution of M032, an attenuated herpes simplex virus type 1 expressing hIL-12, after intracerebral administration to aotus nonhuman primates. Human gene therapy Clinical development 2014; 25:16-27; PMID:24649838; 10.1089/humc.2013.201
94. J.John, G.P.L.Nemunaitis, A.Haythem, F.Lebel, J.A.Barrett, T.Reed, S.Krishnan, J.Lewis, L.Norton. Ad-RTS-hIL-12 + veledimex regulation of IL-12 expression in advanced Breast Cancer (BC) and Melanoma Patients. AACR Annual Meeting 2014, 2014
95. S.Ali, G.D.King, J.F.Curtin, M.Candolfi, W.Xiong, C.Liu, M.Puntel, Q.Cheng, J.Prieto, A.Ribas et al. Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model. Cancer Res 2005; 65:7194-204; PMID:16103070; 10.1158/0008-5472.CAN-04-3434
96. J.F.Curtin, N.Liu, M.Candolfi, W.Xiong, H.Assi, K.Yagiz, M.R.Edwards, K.S.Michelsen, K.M.Kroeger, C.Liu et al. HMGB1 mediates endogenous TLR2 activation and brain tumor regression. PLoS Med 2009; 6:e10; PMID:19143470; 10.1371/journal.pmed.1000010
97. T.T.Tran, M.Uhl, J.Y.Ma, L.Janssen, V.Sriram, S.Aulwurm, I.Kerr, A.Lam, H.K.Webb, A.M.Kapoun et al. Inhibiting TGF-beta signaling restores immune surveillance in the SMA-560 glioma model. Neuro Oncol 2007; 9:259-70; PMID:17522330; 10.1215/15228517-2007-010
98. J.Yu, C.Wheeler, P.Zeltzer, H.Ying, D.Finger, P.Lee, W.Yong, F.Incardona, R.Thompson, M.Riedinger et al. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 2001; 61:842-7; PMID:11221866
99. X.Zhu, B.A.Fallert-Junecko, M.Fujita, R.Ueda, G.Kohanbash, E.R.Kastenhuber, H.A.McDonald, Y.Liu, P.Kalinski, T.A.Reinhart et al. Poly-ICLC promotes the infiltration of effector T cells into intracranial gliomas via induction of CXCL10 in IFN-alpha and IFN-gamma dependent manners. Cancer Immunol Immunother 2010; 59:1401-9; PMID:20549206; 10.1007/s00262-010-0876-3
100. X.Zhu, F.Nishimura, K.Sasaki, M.Fujita, J.E.Dusak, J.Eguchi, W.Fellows-Mayle, W.J.Storkus, P.R.Walker, A.M.Salazar et al. Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models. J Transl Med 2007; 5:10; PMID:17295916; 10.1186/1479-5876-5-10
101. N.Butowski, S.M.Chang, L.Junck, L.M.DeAngelis, L.Abrey, K.Fink, T.Cloughesy, K.R.Lamborn, A.M.Salazar, M.D.Prados. A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05). J Neurooncol 2009; 91:175-82; PMID:18797818; 10.1007/s11060-008-9693-3
102. A.Carpentier, P.Metellus, R.Ursu, S.Zohar, F.Lafitte, M.Barrie, Y.Meng, M.Richard, C.Parizot, F.Laigle-Donadey et al. Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study. Neuro Oncol 2010; 12:401-8; PMID:20308317; 10.1093/neuonc/nop047
103. M.R.Rosenfeld, M.C.Chamberlain, S.A.Grossman, D.M.Peereboom, G.J.Lesser, T.T.Batchelor, S.Desideri, A.M.Salazar, X.Ye. A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma. Neuro Oncol 2010; 12:1071-7; PMID:20615924; 10.1093/neuonc/noq071
104. O.Bloch, C.A.Crane, Y.Fuks, R.Kaur, M.K.Aghi, M.S.Berger, N.A.Butowski, S.M.Chang, J.L.Clarke, M.W.McDermott et al. Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial. Neuro Oncol 2014; 16:274-9; PMID:24335700; 10.1093/neuonc/not203
105. C.A.Crane, S.J.Han, B.Ahn, J.Oehlke, V.Kivett, A.Fedoroff, N.Butowski, S.M.Chang, J.Clarke, M.S.Berger et al. Individual patient-specific immunity against high-grade glioma after vaccination with autologous tumor derived peptides bound to the 96 KD chaperone protein. Clin Cancer Res 2013; 19:205-14; PMID:22872572; 10.1158/1078-0432.CCR-11-3358
106. S.Ramalingam, J.Crawford, A.Chang, C.Manegold, R.Perez-Soler, J.Y.Douillard, N.Thatcher, F.Barlesi, T.Owonikoko, Y.Wang et al. Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial). Ann Oncol 2013; 24:2875-80; PMID:24050956; 10.1093/annonc/mdt371
107. D.Schadendorf, S.Ugurel, B.Schuler-Thurner, F.O.Nestle, A.Enk, E.B.Brocker, S.Grabbe, W.Rittgen, L.Edler, A.Sucker et al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol 2006; 17:563-70; PMID:16418308; 10.1093/annonc/mdj138
108. E.J.Small, P.F.Schellhammer, C.S.Higano, C.H.Redfern, J.J.Nemunaitis, F.H.Valone, S.S.Verjee, L.A.Jones, R.M.Hershberg. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006; 24:3089-94; PMID:16809734; 10.1200/JCO.2005.04.5252
109. M.Fletcher, M.E.Ramirez, R.A.Sierra, P.Raber, P.Thevenot, A.A.Al-Khami, D.Sanchez-Pino, C.Hernandez, D.D.Wyczechowska, A.C.Ochoa et al. l-Arginine depletion blunts antitumor T-cell responses by inducing myeloid-derived suppressor cells. Cancer Res 2015; 75:275-83; PMID:25406192; 10.1158/0008-5472.CAN-14-1491
110. M.D.Lieberman, K.Nishioka, H.P.Redmond, J.M.Daly. Enhancement of interleukin-2 immunotherapy with L-arginine. Ann Surg 1992; 215:157-65; PMID:1546902; 10.1097/00000658-199202000-00011
111. S.F.Hussain, L.Y.Kong, J.Jordan, C.Conrad, T.Madden, I.Fokt, W.Priebe, A.B.Heimberger. A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients. Cancer Res 2007; 67:9630-6; PMID:17942891; 10.1158/0008-5472.CAN-07-1243
112. L.Y.Kong, A.S.Wu, T.Doucette, J.Wei, W.Priebe, G.N.Fuller, W.Qiao, R.Sawaya, G.Rao, A.B.Heimberger. Intratumoral mediated immunosuppression is prognostic in genetically engineered murine models of glioma and correlates to immunotherapeutic responses. Clin Cancer Res 2010; 16:5722-33; PMID:20921210; 10.1158/1078-0432.CCR-10-1693
113. A.Wu, J.Wei, L.Y.Kong, Y.Wang, W.Priebe, W.Qiao, R.Sawaya, A.B.Heimberger. Glioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro Oncol 2010; 12:1113-25; PMID:20667896; 10.1093/neuonc/noq082
114. T.Oh, S.Fakurnejad, E.T.Sayegh, A.J.Clark, M.E.Ivan, M.Z.Sun, M.Safaee, O.Bloch, C.D.James, A.T.Parsa. Immunocompetent murine models for the study of glioblastoma immunotherapy. J Transl Med 2014; 12:107; PMID:24779345; 10.1186/1479-5876-12-107
115. H.Soliman, F.Khalil, S.Antonia. PD-L1 expression is increased in a subset of basal type breast cancer cells. PLoS One 2014; 9:e88557; PMID:24551119; 10.1371/journal.pone.0088557
116. A.Snyder, V.Makarov, T.Merghoub, J.Yuan, J.M.Zaretsky, A.Desrichard, L.A.Walsh, M.A.Postow, P.Wong, T.S.Ho et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014; 371:2189-99; PMID:25409260; 10.1056/NEJMoa1406498
117. S.Champiat, C.Ferte, S.Lebel-Binay, A.Eggermont, J.C.Soria. Exomics and immunogenics: Bridging mutational load and immune checkpoints efficacy. Oncoimmunology 2014; 3:e27817; PMID:24605269; 10.4161/onci.27817
118. E.M.Van Allen, D.Miao, B.Schilling, S.A.Shukla, C.Blank, L.Zimmer, A.Sucker, U.Hillen, M.H.Geukes Foppen, S.M.Goldinger et al. Genomic correlates of response to CTLA4 blockade in metastatic melanoma. Science 2015; 9;350(6257):207–11; PMID:26359337; 10.1126/science.aad0095.
119. M.B.Atkins, M.T.Lotze, J.P.Dutcher, R.I.Fisher, G.Weiss, K.Margolin, J.Abrams, M.Sznol, D.Parkinson, M.Hawkins et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999; 17:2105-16; PMID:10561265
120. D.F.McDermott, M.M.Regan, J.I.Clark, L.E.Flaherty, G.R.Weiss, T.F.Logan, J.M.Kirkwood, M.S.Gordon, J.A.Sosman, M.S.Ernstoff et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005; 23:133-41; PMID:15625368; 10.1200/JCO.2005.03.206
121. O.M.Grauer, J.W.Molling, E.Bennink, L.W.Toonen, R.P.Sutmuller, S.Nierkens, G.J.Adema. TLR ligands in the local treatment of established intracerebral murine gliomas. J Immunol 2008; 181:6720-9; PMID:18981089; 10.4049/jimmunol.181.10.6720
122. H.Okada, L.H.Butterfield, R.L.Hamilton, A.Hoji, M.Sakaki, B.J.Ahn, G.Kohanbash, J.Drappatz, J.Engh, N.Amankulor et al. Induction of robust type-I CD8+ T-cell responses in WHO grade 2 low-grade glioma patients receiving peptide-based vaccines in combination with poly-ICLC. Clin Cancer Res 2015; 21:286-94; PMID:25424847; 10.1158/1078-0432.CCR-14-1790
123. I.F.Pollack, R.I.Jakacki, L.H.Butterfield, R.L.Hamilton, A.Panigrahy, D.M.Potter, A.K.Connelly, S.A.Dibridge, T.L.Whiteside, H.Okada. Antigen-specific immune responses and clinical outcome after vaccination with glioma-associated antigen peptides and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in children with newly diagnosed malignant brainstem and nonbrainstem gliomas. J Clin Oncol 2014; 32:2050-8; PMID:24888813; 10.1200/JCO.2013.54.0526
124. Large-Scale Production of Monoclonal Antibodies. In: Antibodies. NRCUCoMoPM, ed. Monoclonal Antibody Production. Washington, DC: National Academies Press (US), 1999.
125. A.F.Shaughnessy. Monoclonal antibodies: magic bullets with a hefty price tag. BMJ 2012; 345:e8346; PMID:23236036; 10.1136/bmj.e8346
126. K.Frei, D.Gramatzki, I.Tritschler, J.J.Schroeder, L.Espinoza, E.J.Rushing, M.Weller. Transforming growth factor-beta pathway activity in glioblastoma. Oncotarget 2015; 6:5963-77; PMID:25849941; 10.18632/oncotarget.3467
127. P.K.Srivastava, H.Udono, N.E.Blachere, Z.Li. Heat shock proteins transfer peptides during antigen processing and CTL priming. [Review] [52 refs]. Immunogenetics 1994; 39:93-8; PMID:8276462; 10.1007/BF00188611
128. X.Hu, W.Miao, Y.Zou, W.Zhang, Y.Zhang, H.Liu. Expression of p53, epidermal growth factor receptor, Ki-67 and O-methylguanine-DNA methyltransferase in human gliomas. Oncology letters 2013; 6:130-4; PMID:23946790; 10.3892/ol.2013.1317
129. M.K.Nicholas, R.V.Lukas, N.F.Jafri, L.Faoro, R.Salgia. Epidermal growth factor receptor - mediated signal transduction in the development and therapy of gliomas. Clin Cancer Res 2006; 12:7261-70; PMID:17189397; 10.1158/1078-0432.CCR-06-0874
130. F.Szulzewsky, A.Pelz, X.Feng, M.Synowitz, D.Markovic, T.Langmann, I.R.Holtman, X.Wang, B.J.Eggen, H.W.Boddeke et al. Glioma-associated microglia/macrophages display an expression profile different from m1 and m2 polarization and highly express gpnmb and spp1. PLoS One 2015; 10:e0116644; PMID:25658639; 10.1371/journal.pone.0116644
131. K.Dziurzynski, S.M.Chang, A.B.Heimberger, R.F.Kalejta, S.R.McGregor Dallas, M.Smit, L.Soroceanu, C.S.Cobbs. Consensus on the role of human cytomegalovirus in glioblastoma. Neuro Oncol 2012; 14:246-55; PMID:22319219; 10.1093/neuonc/nor227
132. W.Debinski, D.M.Gibo, S.W.Hulet, J.R.Connor, G.Y.Gillespie. Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas. Clin Cancer Res 1999; 5:985-90; PMID:10353730
133. W.Debinski, D.M.Gibo, B.Slagle, S.K.Powers, G.Y.Gillespie. Receptor for interleukin 13 is abundantly and specifically over-expressed in patients with glioblastoma multiforme. Int J Oncol 1999; 15:481-6; PMID:10427128; 10.3892/ijo.15.3.481
134. M.E.Lacouture, J.C.Morris, D.P.Lawrence, A.R.Tan, T.E.Olencki, G.I.Shapiro, B.J.Dezube, J.A.Berzofsky, F.J.Hsu, J.Guitart. Cutaneous keratoacanthomas/squamous cell carcinomas associated with neutralization of transforming growth factor beta by the monoclonal antibody fresolimumab (GC1008). Cancer Immunol Immunother 2015; 64:437-46; PMID:25579378; 10.1007/s00262-015-1653-0
135. J.Nemunaitis, R.O.Dillman, P.O.Schwarzenberger, N.Senzer, C.Cunningham, J.Cutler, A.Tong, P.Kumar, B.Pappen, C.Hamilton et al. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J Clin Oncol 2006; 24:4721-30; PMID:16966690; 10.1200/JCO.2005.05.5335
136. J.Nemunaitis, M.Nemunaitis, N.Senzer, P.Snitz, C.Bedell, P.Kumar, B.Pappen, P.B.Maples, D.Shawler, H.Fakhrai. Phase II trial of Belagenpumatucel-L, a TGF-beta2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients. Cancer Gene Ther 2009; 16:620-4; PMID:19287371; 10.1038/cgt.2009.15
137. A.Testori, J.Richards, E.Whitman, G.B.Mann, J.Lutzky, L.Camacho, G.Parmiani, G.Tosti, J.M.Kirkwood, A.Hoos et al. Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group. J Clin Oncol 2008; 26:955-62; PMID:18281670; 10.1200/JCO.2007.11.9941
138. P.W.Kantoff, C.S.Higano, N.D.Shore, E.R.Berger, E.J.Small, D.F.Penson, C.H.Redfern, A.C.Ferrari, R.Dreicer, R.B.Sims et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363:411-22; PMID:20818862; 10.1056/NEJMoa1001294
139. S.M.Ansell, A.M.Lesokhin, I.Borrello, A.Halwani, E.C.Scott, M.Gutierrez, S.J.Schuster, M.M.Millenson, D.Cattry, G.J.Freeman et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015; 372:311-9; PMID:25482239; 10.1056/NEJMoa1411087
140. J.R.Brahmer, H.Hammers, E.J.Lipson. Nivolumab: targeting PD-1 to bolster antitumor immunity. Future Oncol 2015; 11:1307-26; PMID:25798726; 10.2217/fon.15.52
141. J.Brayer, M.Fishman. Regression of metastatic clear cell kidney cancer with interleukin-2 treatment following nivolumab (anti-PD-1) treatment. J Immunother 2014; 37:187-91; PMID:24598453; 10.1097/CJI.0000000000000024
142. E.Faghfuri, M.A.Faramarzi, S.Nikfar, M.Abdollahi. Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma. Expert Rev Anticancer Ther 2015; 15:981-93; PMID:26313415; 10.1586/14737140.2015.1074862
143. D.M.Geynisman. Anti-programmed Cell Death Protein 1 (PD-1) Antibody Nivolumab Leads to a Dramatic and Rapid Response in Papillary Renal Cell Carcinoma with Sarcomatoid and Rhabdoid Features. Eur Urol 2015; 68(5):912-4; PMID:26194044; 10.1016/j.eururo.2015.07.008.
144. S.L.Topalian, F.S.Hodi, J.R.Brahmer, S.N.Gettinger, D.C.Smith, D.F.McDermott, J.D.Powderly, R.D.Carvajal, J.A.Sosman, M.B.Atkins et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366:2443-54; PMID:22658127; 10.1056/NEJMoa1200690
145. A.K.Palucka, M.V.Dhodapkar, S.Paczesny, S.Burkeholder, K.M.Wittkowski, R.M.Steinman, J.Fay, J.Banchereau. Single injection of CD34+ progenitor-derived dendritic cell vaccine can lead to induction of T-cell immunity in patients with stage IV melanoma. J Immunother 2003; 26:432-9; PMID:12973032; 10.1097/00002371-200309000-00006
146. A.K.Palucka, M.V.Dhodapkar, S.Paczesny, H.Ueno, J.Fay, J.Banchereau. Boosting vaccinations with peptide-pulsed CD34+ progenitor-derived dendritic cells can expand long-lived melanoma peptide-specific CD8+ T cells in patients with metastatic melanoma. J Immunother 2005; 28:158-68; PMID:15725960; 10.1097/01.cji.0000154249.74383.17
147. M.Podrazil, R.Horvath, E.Becht, D.Rozkova, P.Bilkova, K.Sochorova, H.Hromadkova, J.Kayserova, K.Vavrova, J.Lastovicka et al. Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer. Oncotarget 2015; 6:18192-205; PMID:26078335; 10.18632/oncotarget.4145
148. K.Kawakami, S.R.Husain, M.Kawakami, R.K.Puri. Improved anti-tumor activity and safety of interleukin-13 receptor targeted cytotoxin by systemic continuous administration in head and neck cancer xenograft model. Mol Med 2002; 8:487-94; PMID:12435859
149. K.Kawakami, M.Kawakami, B.H.Joshi, R.K.Puri. Interleukin-13 receptor-targeted cancer therapy in an immunodeficient animal model of human head and neck cancer. Cancer Res 2001; 61:6194-200; PMID:11507072
150. M.Kioi, M.Kawakami, T.Shimamura, S.R.Husain, R.K.Puri. Interleukin-13 receptor alpha2 chain: a potential biomarker and molecular target for ovarian cancer therapy. Cancer 2006; 107:1407-18; PMID:16902988; 10.1002/cncr.22134
151. Y.Komohara, H.Horlad, K.Ohnishi, K.Ohta, K.Makino, H.Hondo, R.Yamanaka, K.Kajiwara, T.Saito, J.Kuratsu et al. M2 macrophage/microglial cells induce activation of Stat3 in primary central nervous system lymphoma. Journal of clinical and experimental hematopathology: JCEH 2011; 51:93-9; PMID:22104307; 10.3960/jslrt.51.93
152. M.J.van den Bent, Y.Gao, M.Kerkhof, J.M.Kros, T.Gorlia, K.van Zwieten, J.Prince, S.van Duinen, P.A.Sillevis Smitt, M.Taphoorn et al. Changes in the EGFR amplification and EGFRvIII expression between paired primary and recurrent glioblastomas. Neuro Oncol 2015; 17:935-41; PMID:25691693; 10.1093/neuonc/nov013
153. S.Lv, E.Teugels, J.Sadones, S.De Brakeleer, J.Duerinck, S.Du Four, A.Michotte, J.De Greve, B.Neyns. Correlation of EGFR, IDH1 and PTEN status with the outcome of patients with recurrent glioblastoma treated in a phase II clinical trial with the EGFR-blocking monoclonal antibody cetuximab. Int J Oncol 2012; 41:1029-35; PMID:22752145; 10.3892/ijo.2012.1539188
154. T.Martens, Y.Laabs, H.S.Gunther, D.Kemming, Z.Zhu, L.Witte, C.Hagel, M.Westphal, K.Lamszus. Inhibition of glioblastoma growth in a highly invasive nude mouse model can be achieved by targeting epidermal growth factor receptor but not vascular endothelial growth factor receptor-2. Clin Cancer Res 2008; 14:5447-58; PMID:18765536; 10.1158/1078-0432.CCR-08-0147
155. P.Agarwalla, Z.Barnard, P.Fecci, G.Dranoff, W.T.Curry, Jr. Sequential immunotherapy by vaccination with GM-CSF-expressing glioma cells and CTLA-4 blockade effectively treats established murine intracranial tumors. J Immunother 2012; 35:385-9; PMID:22576343; 10.1097/CJI.0b013e3182562d59
156. K.S.Peggs, S.A.Quezada, C.A.Chambers, A.J.Korman, J.P.Allison. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med 2009; 206:1717-25; PMID:19581407; 10.1084/jem.20082492
157. S.A.Quezada, K.S.Peggs, M.A.Curran, J.P.Allison. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. Journal of Clinical Investigation 2006; 116:1935-45; PMID:16778987; 10.1172/JCI27745
158. S.Kong, S.Sengupta, B.Tyler, A.J.Bais, Q.Ma, S.Doucette, J.Zhou, A.Sahin, B.S.Carter, H.Brem et al. Suppression of human glioma xenografts with second-generation IL13R-specific chimeric antigen receptor-modified T cells. Clin Cancer Res 2012; 18:5949-60; PMID:22966020; 10.1158/1078-0432.CCR-12-0319
159. A.M.Scott, F.T.Lee, N.Tebbutt, R.Herbertson, S.S.Gill, Z.Liu, E.Skrinos, C.Murone, T.H.Saunder, B.Chappell et al. A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors. Proc Natl Acad Sci U S A 2007; 104:4071-6; PMID:17360479; 10.1073/pnas.0611693104
160. S.J.Coniglio, E.Eugenin, K.Dobrenis, E.R.Stanley, B.L.West, M.H.Symons, J.E.Segall. Microglial stimulation of glioblastoma invasion involves epidermal growth factor receptor (EGFR) and colony stimulating factor 1 receptor (CSF-1R) signaling. Mol Med 2012; 18:519-27; PMID:22294205; 10.2119/molmed.2011.00217
161. D.S.Markovic, K.Vinnakota, S.Chirasani, M.Synowitz, H.Raguet, K.Stock, M.Sliwa, S.Lehmann, R.Kalin, N.van Rooijen et al. Gliomas induce and exploit microglial MT1-MMP expression for tumor expansion. Proc Natl Acad Sci U S A 2009; 106:12530-5; PMID:19617536; 10.1073/pnas.0804273106
162. J.E.Kim, M.A.Patel, A.Mangraviti, E.Velarde, D.Theodros, D.Mathios, C.M.Jackson, B.Tyler, X.Ye, H.Brem et al. 143 The Combination of anti-TIM-3 and anti-PD-1 Checkpoint Inhibitors With Focused Radiation Resulted in a Synergistic Antitumor Immune Response in a Preclinical Glioma Model. Neurosurgery 2015; 62 Suppl 1:212; 10.1227/01.neu.0000467105.60300.04
163. S.Penuelas, J.Anido, R.M.Prieto-Sanchez, G.Folch, I.Barba, I.Cuartas, D.Garcia-Dorado, M.A.Poca, J.Sahuquillo, J.Baselga et al. TGF-beta increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma. Cancer Cell 2009; 15:315-27; PMID:19345330; 10.1016/j.ccr.2009.02.011
164. M.E.Hardee, A.E.Marciscano, C.M.Medina-Ramirez, D.Zagzag, A.Narayana, S.M.Lonning, M.H.Barcellos-Hoff. Resistance of glioblastoma-initiating cells to radiation mediated by the tumor microenvironment can be abolished by inhibiting transforming growth factor-beta. Cancer Res 2012; 72:4119-29; PMID:22693253; 10.1158/0008-5472.CAN-12-0546
165. T.Randriarimanana, A.Chateau, B.Faivre, S.Pinel, C.Boura. Sensitivity of glioma initiating cells to a monoclonal anti-EGFR antibody therapy under hypoxia. Life Sci 2015; 137:74-80; PMID:26239438; 10.1016/j.lfs.2015.07.024
166. Q.Xu, G.Liu, X.Yuan, M.Xu, H.Wang, J.Ji, B.Konda, K.L.Black, J.S.Yu. Antigen-specific T-cell response from dendritic cell vaccination using cancer stem-like cell-associated antigens. Stem Cells 2009; 27:1734-40; PMID:19536809; 10.1002/stem.102
167. S.Pellegatta, P.L.Poliani, D.Corno, F.Menghi, F.Ghielmetti, B.Suarez-Merino, V.Caldera, S.Nava, M.Ravanini, F.Facchetti et al. Neurospheres enriched in cancer stem-like cells are highly effective in eliciting a dendritic cell-mediated immune response against malignant gliomas. Cancer Res 2006; 66:10247-52; PMID:17079441; 10.1158/0008-5472.CAN-06-2048
168. E.O.Vik-Mo, M.Nyakas, B.V.Mikkelsen, M.C.Moe, P.Due-Tonnesen, E.M.Suso, S.Saeboe-Larssen, C.Sandberg, J.E.Brinchmann, E.Helseth et al. Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma. Cancer Immunol Immunother 2013; 62:1499-509; PMID:23817721; 10.1007/s00262-013-1453-3
169. X.Zhu, S.Prasad, S.Gaedicke, M.Hettich, E.Firat, G.Niedermann. Patient-derived glioblastoma stem cells are killed by CD133-specific CAR T cells but induce the T cell aging marker CD57. Oncotarget 2015; 6:171-84; PMID:25426558; 10.18632/oncotarget.2767
170. Q.Wei, L.Clarke, D.K.Scheidenhelm, B.Qian, A.Tong, N.Sabha, Z.Karim, N.A.Bock, R.Reti, R.Swoboda et al. High-grade glioma formation results from postnatal pten loss or mutant epidermal growth factor receptor expression in a transgenic mouse glioma model. Cancer Res 2006; 66:7429-37; PMID:16885338; 10.1158/0008-5472.CAN-06-0712
171. E.C.Holland, W.P.Hively, R.A.DePinho, H.E.Varmus. A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice. Genes Dev 1998; 12:3675-85; PMID:9851974; 10.1101/gad.12.23.3675
172. Z.Belcaid, J.A.Phallen, J.Zeng, A.P.See, D.Mathios, C.Gottschalk, S.Nicholas, M.Kellett, J.Ruzevick, C.Jackson et al. Focal radiation therapy combined with 4-1BB activation and CTLA-4 blockade yields long-term survival and a protective antigen-specific memory response in a murine glioma model. PLoS One 2014; 9:e101764; PMID:25013914; 10.1371/journal.pone.0101764
173. J.Vom Berg, M.Vrohlings, S.Haller, A.Haimovici, P.Kulig, A.Sledzinska, M.Weller, B.Becher. Intratumoral IL-12 combined with CTLA-4 blockade elicits T cell-mediated glioma rejection. J Exp Med 2013; 210:2803-11; PMID:24277150; 10.1084/jem.20130678
174. P.E.Fecci, A.E.Sweeney, P.M.Grossi, S.K.Nair, C.A.Learn, D.A.Mitchell, X.Cui, T.J.Cummings, D.D.Bigner, E.Gilboa et al. Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells. Clin Cancer Res 2006; 12:4294-305; PMID:16857805; 10.1158/1078-0432.CCR-06-0053
175. S.K.Jacobs, D.J.Wilson, P.L.Kornblith, E.A.Grimm. In vitro killing of human glioblastoma by interleukin-2- activated autologous lymphocytes. JNeurosurg 1986; 64:114-7; PMID:3001247; 10.3171/jns.1986.64.1.0114
176. S.K.Jacobs, G.Melin, B.Holcomb, C.W.Parham, P.L.Kornblith, E.A.Grimm. Lymphokine activated killer (LAK) cell-mediated lysis of murine glioma: trypsin-chymotrypsin-sensitive glioma protein is responsible for tumor-selective recognition by LAK cells. Brain Res 1986; 372:386-9; PMID:3486696; 10.1016/0006-8993(86)91150-9
177. S.K.Jacobs, C.W.Parham, B.Holcomb, B.Ikejiri, P.L.Kornblith, E.A.Grimm. Lymphokine activated killer (LAK) cell mediated killing of human glioma: effect of pretreating glioma with various membrane modifying agents. J Neurooncol 1987; 5:5-10; PMID:3037036; 10.1007/BF00162760
178. P.Wang, J.P.Yu, S.Y.Gao, X.M.An, X.B.Ren, X.G.Wang, W.L.Li. Experimental study on the treatment of intracerebral glioma xenograft with human cytokine-induced killer cells. Cell Immunol 2008; 253:59-65; PMID:18522858; 10.1016/j.cellimm.2008.04.014
179. A.Poli, J.Wang, O.Domingues, J.Planaguma, T.Yan, C.B.Rygh, K.O.Skaftnesmo, F.Thorsen, E.McCormack, F.Hentges et al. Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival. Oncotarget 2013; 4:1527-46; PMID:24127551; 10.18632/oncotarget.1291
180. J.A.Barrett, C.Hongliang, J.Miao, M.Murray, E.Gable, D.Blake, S.Krishnan, E.A.Chiocca, S.Nagpal, J.Raizer, et al. Intratumoral regulated expression of IL-12 as a gene therapy approach to treatment of glioma. Neuro Oncol 2015; 17(suppl 5):v113–v115; doi: http://dx.doi.org/10.1093/neuonc/nov217.03.
181. J.H.Sampson, G.E.Archer, D.A.Mitchell, A.B.Heimberger, J.E.Herndon, 2nd, D.Lally-Goss, S.McGehee-Norman, A.Paolino, D.A.Reardon, A.H.Friedman et al. An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Mol Cancer Ther 2009; 8:2773-9; PMID:19825799; 10.1158/1535-7163.MCT-09-0124
182. R.Schlingensiepen, M.Goldbrunner, M.N.Szyrach, G.Stauder, P.Jachimczak, U.Bogdahn, F.Schulmeyer, P.Hau, K.H.Schlingensiepen. Intracerebral and intrathecal infusion of the TGF-beta 2-specific antisense phosphorothioate oligonucleotide AP 12009 in rabbits and primates: toxicology and safety. Oligonucleotides 2005; 15:94-104; PMID:15989424; 10.1089/oli.2005.15.94
183. B.Hasselbalch, U.Lassen, S.Hansen, M.Holmberg, M.Sorensen, M.Kosteljanetz, H.Broholm, M.T.Stockhausen, H.S.Poulsen. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial. Neuro Oncol 2010; 12:508-16; PMID:20406901; 10.1093/neuonc/nop063
184. S.M.Ansell, S.A.Hurvitz, P.A.Koenig, B.R.LaPlant, B.F.Kabat, D.Fernando, T.M.Habermann, D.J.Inwards, M.Verma, R.Yamada et al. Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res 2009; 15:6446-53; PMID:19808874; 10.1158/1078-0432.CCR-09-1339
185. H.Horinouchi, N.Yamamoto, Y.Fujiwara, I.Sekine, H.Nokihara, K.Kubota, S.Kanda, S.Yagishita, H.Wakui, S.Kitazono et al. Phase I study of ipilimumab in phased combination with paclitaxel and carboplatin in Japanese patients with non-small-cell lung cancer. Invest New Drugs 2015; 33:881-9; PMID:25924991; 10.1007/s10637-015-0243-5
186. D.McDermott, J.Haanen, T.T.Chen, P.Lorigan, S.O'Day, M.D.X.Investigators. Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20). Ann Oncol 2013; 24:2694-8; PMID:23942774; 10.1093/annonc/mdt291
187. S.J.O'Day, M.Maio, V.Chiarion-Sileni, T.F.Gajewski, H.Pehamberger, I.N.Bondarenko, P.Queirolo, L.Lundgren, S.Mikhailov, L.Roman et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol 2010; 21:1712-7; PMID:20147741; 10.1093/annonc/mdq013
188. J.Weber, O.Hamid, A.Amin, S.O'Day, E.Masson, S.M.Goldberg, D.Williams, S.M.Parker, S.D.Chasalow, S.Alaparthy et al. Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma. Cancer Immun 2013; 13:7; PMID:23833564
189. J.S.Weber, A.Amin, D.Minor, J.Siegel, D.Berman, S.J.O'Day. Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial. Melanoma Res 2011; 21:530-4; PMID:22051508; 10.1097/CMR.0b013e32834d3d88
190. J.S.Weber, S.O'Day, W.Urba, J.Powderly, G.Nichol, M.Yellin, J.Snively, E.Hersh. Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol 2008; 26:5950-6; PMID:19018089; 10.1200/JCO.2008.16.1927
191. C.N.Chang, Y.C.Huang, D.M.Yang, K.Kikuta, K.J.Wei, T.Kubota, W.K.Yang. A phase I/II clinical trial investigating the adverse and therapeutic effects of a postoperative autologous dendritic cell tumor vaccine in patients with malignant glioma. J Clin Neurosci 2011; 18:1048-54; PMID:21715171; 10.1016/j.jocn.2010.11.034
192. K.Iwami, S.Shimato, M.Ohno, H.Okada, N.Nakahara, Y.Sato, J.Yoshida, S.Suzuki, H.Nishikawa, H.Shiku et al. Peptide-pulsed dendritic cell vaccination targeting interleukin-13 receptor alpha2 chain in recurrent malignant glioma patients with HLA-A*24/A*02 allele. Cytotherapy 2012; 14:733-42; PMID:22424217; 10.3109/14653249.2012.666633
193. S.Phuphanich, C.J.Wheeler, J.D.Rudnick, M.Mazer, H.Wang, M.A.Nuno, J.E.Richardson, X.Fan, J.Ji, R.M.Chu et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. Cancer Immunol Immunother 2013; 62:125-35; PMID:22847020; 10.1007/s00262-012-1319-0
194. R.Trepiakas, A.Berntsen, S.R.Hadrup, J.Bjorn, P.F.Geertsen, P.T.Straten, M.H.Andersen, A.E.Pedersen, A.Soleimani, T.Lorentzen et al. Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial. Cytotherapy 2010; 12:721-34; PMID:20429791; 10.3109/14653241003774045
195. R.Yamanaka, T.Abe, N.Yajima, N.Tsuchiya, J.Homma, T.Kobayashi, M.Narita, M.Takahashi, R.Tanaka. Vaccination of recurrent glioma patients with tumor lysate-pulsed dendritic cells elicits immune responses: Results of a clinical phase I/II trial. Br J Cancer 2003; 89:1172-9; PMID:14520441; 10.1038/sj.bjc.6601268
196. J.J.Nemunaitis, G.P.Linette, O.Hamid, S.S.Agarwala, A.Starodub, L.Sun, F.Lebel, J.A.Barrett, J.Lewis. Regulated intratumoral expression of IL-12 as a basis for combination therapy in melanoma. J Transl Med. 2014; 12(Suppl 1):O11; http:dx.doi.org/10.1186/1479-5876-12-S1-O11.
197. J.H.Sampson, G.E.Archer, D.A.Mitchell, A.B.Heimberger, D.D.Bigner. Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma. Semin Immunol 2008; 20:267-75; PMID:18539480; 10.1016/j.smim.2008.04.001
198. C.Lebbe, J.S.Weber, M.Maio, B.Neyns, K.Harmankaya, O.Hamid, S.J.O'Day, C.Konto, L.Cykowski, M.B.McHenry et al. Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies. Ann Oncol 2014; 25:2277-84; PMID:25210016; 10.1093/annonc/mdu441
199. B.Neyns, J.Sadones, E.Joosens, F.Bouttens, L.Verbeke, J.F.Baurain, L.D'Hondt, T.Strauven, C.Chaskis, P.In't Veld et al. Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma. Ann Oncol 2009; 20:1596-603; PMID:19491283; 10.1093/annonc/mdp032
200. H.Fakhrai, J.C.Mantil, L.Liu, G.L.Nicholson, C.S.Murphy-Satter, J.Ruppert, D.L.Shawler. Phase I clinical trial of a TGF-beta antisense-modified tumor cell vaccine in patients with advanced glioma. Cancer Gene Ther 2006; 13:1052-60; PMID:16826191; 10.1038/sj.cgt.7700975
201. K.Mitsuka, T.Kawataki, E.Satoh, T.Asahara, T.Horikoshi, H.Kinouchi. Expression of indoleamine 2,3-dioxygenase and correlation with pathological malignancy in gliomas. Neurosurgery 2013; 72:1031-8; discussion 8-9; PMID:23426156; 10.1227/NEU.0b013e31828cf945
202. D.A.Wainwright, I.V.Balyasnikova, A.L.Chang, A.U.Ahmed, K.S.Moon, B.Auffinger, A.L.Tobias, Y.Han, M.S.Lesniak. IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival. Clin Cancer Res 2012; 18:6110-21; PMID:22932670; 10.1158/1078-0432.CCR-12-2130
203. A.Horiguchi, M.Oya, K.Marumo, M.Murai. STAT3, but not ERKs, mediates the IL-6-induced proliferation of renal cancer cells, ACHN and 769P. Kidney international 2002; 61:926-38; PMID:11849447; 10.1046/j.1523-1755.2002.00206.x
204. J.D.Khoury, L.J.Medeiros, G.Rassidakis, M.A.Yared, P.Tsioli, V.Leventaki, A.Schmitt-Graeff, M.Herling, H.M.Amin, R.Lai. Differential expression and clinical significance of tyrosine-phosphorylated STAT3 in ALK+ and ALK- anaplastic large cell lymphoma. Clin Cancer Res 2003; 9:3692-9; PMID:14506160
205. M.Masuda, S.Toh, K.Koike, Y.Kuratomi, M.Suzui, A.Deguchi, S.Komiyama, I.B.Weinstein. The roles of JNK1 and Stat3 in the response of head and neck cancer cell lines to combined treatment with all-trans-retinoic acid and 5-fluorouracil. Jpn J Cancer Res 2002; 93:329-39; PMID:11927016; 10.1111/j.1349-7006.2002.tb02176.x
206. R.M.McLoughlin, B.J.Jenkins, D.Grail, A.Williams, C.Fielding, C.R.Parker, M.Ernst, N.Topley, S.A.Jones. IL-6 trans-signaling via STAT3 directs T cell infiltration in acute inflammation. Proc Natl Acad Sci U S A 2005 102:9589-94; PMID:15976028; 10.1073/pnas.0501794102
207. W.Gong, L.Wang, J.Yao, J.A.Ajani, D.Wei, K.Aldape, K.Xie, R.Sawaya, S.Huang. Expression of activated signal transducer and activator of transcription 3 predicts expression of vascular endothelial growth factor in and angiogenic phenotype of human gastric cancer. Clin Cancer Res 2005; 11:1386-93; PMID:15746037; 10.1158/1078-0432.CCR-04-0487
208. A.Horiguchi, M.Oya, T.Shimada, A.Uchida, K.Marumo, M.Murai. Activation of signal transducer and activator of transcription 3 in renal cell carcinoma: A study of incidence and its association with pathological features and clinical outcome. J Urology 2002; 168:762-5; PMID:12131365; 10.1016/S0022-5347(05)64741-6
209. M.Masuda, M.Suzui, R.Yasumatu. Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. Cancer Res 2002; 62:3351-5; PMID:12067972
210. M.E.Kupferman, A.Jayakumar, G.Zhou, T.Xie, Y.Dakak-Yazici, M.Zhao, J.Ju, M.Mandal, S.Jasser, T.Madden et al. Therapeutic suppression of constitutive and inducible JAK\STAT activation in head and neck squamous cell carcinoma. J Exp Ther Oncol 2009; 8:117-27; PMID:20192118
211. S.Xi, W.E.Gooding, J.R.Grandis. In vivo antitumor efficacy of STAT3 blockade using a transcription factor decoy approach: implications for cancer therapy. Oncogene 2005; 24:970-9; PMID:15592503; 10.1038/sj.onc.1208316
212. J.de Groot, J.Liang, L.Y.Kong, J.Wei, Y.Piao, G.Fuller, W.Qiao, A.B.Heimberger. Modulating antiangiogenic resistance by inhibiting the signal transducer and activator of transcription 3 pathway in glioblastoma. Oncotarget 2012; 3:1036-48; PMID:23013619; 10.18632/oncotarget.663
213. F.E.Bleeker, S.Lamba, S.Leenstra, D.Troost, T.Hulsebos, W.P.Vandertop, M.Frattini, F.Molinari, M.Knowles, A.Cerrato et al. IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat 2009; 30:7-11; PMID:19117336; 10.1002/humu.20937
214. L.Y.Kong, M.K.Abou-Ghazal, J.Wei, A.Chakraborty, W.Sun, W.Qiao, G.N.Fuller, I.Fokt, E.A.Grimm, R.J.Schmittling et al. A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells. Clin Cancer Res 2008; 14:5759-68; PMID:18794085; 10.1158/1078-0432.CCR-08-0377
215. B.D.Choi, C.T.Kuan, M.Cai, G.E.Archer, D.A.Mitchell, P.C.Gedeon, L.Sanchez-Perez, I.Pastan, D.D.Bigner, J.H.Sampson. Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma. Proc Natl Acad Sci U S A 2013; 110:270-5; PMID:23248284; 10.1073/pnas.1219817110
216. J.H.Sampson, B.D.Choi, L.Sanchez-Perez, C.M.Suryadevara, D.J.Snyder, C.T.Flores, R.J.Schmittling, S.K.Nair, E.A.Reap, P.K.Norberg et al. EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss. Clin Cancer Res 2014; 20:972-84; PMID:24352643; 10.1158/1078-0432.CCR-13-0709
217. H.G.Caruso, L.V.Hurton, A.Najjar, D.Rushworth, S.Ang, S.Olivares, T.Mi, K.Switzer, H.Singh, H.Huls et al. Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity. Cancer Res 2015; 75:3505-18; PMID:26330164; 10.1158/0008-5472.CAN-15-0139
218. T.Schumacher, L.Bunse, S.Pusch, F.Sahm, B.Wiestler, J.Quandt, O.Menn, M.Osswald, I.Oezen, M.Ott et al. A vaccine targeting mutant IDH1 induces antitumour immunity. Nature 2014; 512(7514):324-7; PMID:25043048; 10.1038/nature13387.
219. I.Melero, W.W.Shuford, S.A.Newby, A.Aruffo, J.A.Ledbetter, K.E.Hellstrom, R.S.Mittler, L.Chen. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med 1997; 3:682-5; PMID:9176498; 10.1038/nm0697-682
220. K.E.Pollok, Y.J.Kim, Z.Zhou, J.Hurtado, K.K.Kim, R.T.Pickard, B.S.Kwon. Inducible T cell antigen 4-1BB. Analysis of expression and function. J Immunol 1993; 150:771-81; PMID:7678621
221. W.W.Shuford, K.Klussman, D.D.Tritchler, D.T.Loo, J.Chalupny, A.W.Siadak, T.J.Brown, J.Emswiler, H.Raecho, C.P.Larsen et al. 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J Exp Med 1997; 186:47-55; PMID:9206996; 10.1084/jem.186.1.47
222. G.Kong, G.Anyarambhatla, W.P.Petros, R.D.Braun, O.M.Colvin, D.Needham, M.W.Dewhirst. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release. Cancer Res 2000; 60:6950-7; PMID:11156395
223. J.Han, J.Chu, W.Keung Chan, J.Zhang, Y.Wang, J.B.Cohen, A.Victor, W.H.Meisen, S.H.Kim, P.Grandi et al. CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells. Sci Rep 2015; 5:11483; PMID:26155832; 10.1038/srep11483
224. B.Schrand, A.Berezhnoy, R.Brenneman, A.Williams, A.Levay, L.Y.Kong, G.Rao, S.Zhou, A.B.Heimberger, E.Gilboa. Targeting 4-1BB costimulation to the tumor stroma with bispecific aptamer conjugates enhances the therapeutic index of tumor immunotherapy. Cancer Immunol Res 2014; 2:867-77; PMID:24938283; 10.1158/2326-6066.CIR-14-0007
225. A.Iwamaru, S.Szymanski, E.Iwado, H.Aoki, T.Yokoyama, I.Fokt, K.Hess, C.Conrad, T.Madden, R.Sawaya et al. A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo. Oncogene 2007; 26:2435-44; PMID:17043651; 10.1038/sj.onc.1210031
226. E.Kocak, K.Lute, X.Chang, K.F.May, Jr., K.R.Exten, H.Zhang, S.F.Abdessalam, A.M.Lehman, D.Jarjoura, P.Zheng et al. Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity. Cancer Res 2006; 66:7276-84; PMID:16849577; 10.1158/0008-5472.CAN-05-2128
227. B.Schrand, A.Berezhnoy, R.Brenneman, A.Williams, A.Levay, E.Gilboa. Reducing toxicity of 4-1BB costimulation: targeting 4-1BB ligands to the tumor stroma with bi-specific aptamer conjugates. Oncoimmunology 2015; 4:e970918; PMID:25949891; 10.4161/21624011.2014.970918
228. J.M.Daly, J.Reynolds, A.Thom, L.Kinsley, M.Dietrick-Gallagher, J.Shou, B.Ruggieri. Immune and metabolic effects of arginine in the surgical patient. Ann Surg 1988; 208:512-23; PMID:3140744; 10.1097/00000658-198810000-00013